CA3179441A1 - Polypeptide useful in adoptive cell therapy - Google Patents

Polypeptide useful in adoptive cell therapy Download PDF

Info

Publication number
CA3179441A1
CA3179441A1 CA3179441A CA3179441A CA3179441A1 CA 3179441 A1 CA3179441 A1 CA 3179441A1 CA 3179441 A CA3179441 A CA 3179441A CA 3179441 A CA3179441 A CA 3179441A CA 3179441 A1 CA3179441 A1 CA 3179441A1
Authority
CA
Canada
Prior art keywords
seq
sequence
cell
polypeptide
rituximab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3179441A
Other languages
English (en)
French (fr)
Inventor
Marc MARTINEZ-LLORDELLA
Simon BORNSCHEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quell Therapeutics Ltd
Original Assignee
Quell Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quell Therapeutics Ltd filed Critical Quell Therapeutics Ltd
Publication of CA3179441A1 publication Critical patent/CA3179441A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3179441A 2020-05-26 2021-05-26 Polypeptide useful in adoptive cell therapy Pending CA3179441A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2007842.4 2020-05-26
GBGB2007842.4A GB202007842D0 (en) 2020-05-26 2020-05-26 Polypeptide useful in adoptive cell therapy
PCT/EP2021/064053 WO2021239812A1 (en) 2020-05-26 2021-05-26 Polypeptide useful in adoptive cell therapy

Publications (1)

Publication Number Publication Date
CA3179441A1 true CA3179441A1 (en) 2021-12-02

Family

ID=71406309

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3179441A Pending CA3179441A1 (en) 2020-05-26 2021-05-26 Polypeptide useful in adoptive cell therapy

Country Status (9)

Country Link
US (1) US20230183311A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157318A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023527049A (cg-RX-API-DMAC7.html)
CN (1) CN115955977A (cg-RX-API-DMAC7.html)
AU (1) AU2021279184A1 (cg-RX-API-DMAC7.html)
CA (1) CA3179441A1 (cg-RX-API-DMAC7.html)
GB (2) GB202007842D0 (cg-RX-API-DMAC7.html)
TW (1) TW202210503A (cg-RX-API-DMAC7.html)
WO (1) WO2021239812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12227756B2 (en) 2018-04-18 2025-02-18 Ucl Business Ltd Engineered regulatory T cell
TW202321286A (zh) 2021-09-21 2023-06-01 英商圭爾醫療有限公司 抗p75ntr嵌合抗原受體
WO2023047100A1 (en) 2021-09-21 2023-03-30 Quell Therapeutics Ltd Anti-trem2 chimeric antigen receptor
GB202117298D0 (en) 2021-11-30 2022-01-12 Quell Therapeutics Ltd Signalling protein
US20250017967A1 (en) 2021-12-17 2025-01-16 Quell Therapeutics Limited Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells
EP4453022A1 (en) 2021-12-22 2024-10-30 Quell Therapeutics Limited Constitutive cytokine receptors
EP4496883A1 (en) 2022-03-22 2025-01-29 Quell Therapeutics Limited Methods and products for culturing t cells and uses thereof
EP4519294A1 (en) * 2022-05-04 2025-03-12 Earli Inc. Methods using surface-expressable activatable epitopes to localize and/or treat diseased cells
GB202217541D0 (en) 2022-11-24 2023-01-11 Quell Therapeutics Ltd Recombinant receptor
WO2024133472A1 (en) 2022-12-22 2024-06-27 Quell Therapeutics Limited Constitutive cytokine receptors
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
JP2026507781A (ja) 2023-01-23 2026-03-06 メディツィニシェ ホゥーシュル ハノーファー キメラ抗原受容体
CN120787258A (zh) 2023-02-07 2025-10-14 圭尔医疗有限公司 Treg细胞培养方法
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194355A1 (en) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194649A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t cells and uses thereof
WO2024194642A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t regulatory cell
EP4442322A1 (en) 2023-04-06 2024-10-09 Medizinische Hochschule Hannover Liver-specific car for use against immunologic rejection
CN121586727A (zh) 2023-06-21 2026-02-27 圭尔医疗有限公司 组成型细胞因子受体
EP4766382A1 (en) 2023-08-24 2026-07-01 Medizinische Hochschule Hannover BECAUSE FOR THE TREATMENT OF MS OR MA
EP4512415A1 (en) 2023-08-24 2025-02-26 Medizinische Hochschule Hannover Chimeric antigen receptor for treatment of multiple sclerosis or alzheimer's disease
US20260176598A1 (en) 2024-07-04 2026-06-25 Quell Therapeutics Limited Expression construct
EP4678187A1 (en) 2024-07-11 2026-01-14 Medizinische Hochschule Hannover Compound for use in the treatment of inflammatory bowel disease
WO2026027876A1 (en) 2024-07-29 2026-02-05 Quell Therapeutics Limited Chimeric antigen receptor
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2528595A1 (en) 2003-06-13 2005-01-06 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
KR20080039844A (ko) 2005-05-24 2008-05-07 아베스타 겐그레인 테크놀로지스 피브이티 리미티드 B―세포 림프종 치료를 위한 cd20에 대한 모노클로날항체의 제조 방법
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
GB201415344D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Protein
EP3250602A1 (en) * 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
TWI700298B (zh) * 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向b細胞成熟抗原之嵌合型抗原受體類
US10604586B2 (en) 2016-05-09 2020-03-31 Industrial Technology Research Institute Humanized monoclonal antibody and uses thereof
CN110869046B (zh) * 2017-03-31 2025-02-25 塞勒克提斯公司 通用型抗cd22嵌合抗原受体工程化的免疫细胞
MX2020010808A (es) * 2018-04-13 2021-03-02 Sangamo Therapeutics France Receptor de antigeno quimerico especifico para el receptor de interleucina-23.
CN112996819B (zh) * 2018-08-16 2025-11-04 纪念斯隆-凯特琳癌症中心 细胞分选系统及使用方法
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell

Also Published As

Publication number Publication date
GB2611448B (en) 2025-01-08
GB202007842D0 (en) 2020-07-08
JP2023527049A (ja) 2023-06-26
GB2611448A (en) 2023-04-05
TW202210503A (zh) 2022-03-16
EP4157318A1 (en) 2023-04-05
AU2021279184A1 (en) 2022-12-22
GB202218768D0 (en) 2023-01-25
WO2021239812A1 (en) 2021-12-02
US20230183311A1 (en) 2023-06-15
CN115955977A (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
US20230183311A1 (en) Polypeptide useful in adoptive cell therapy
JP7824235B2 (ja) キメラ抗原受容体のための新規コンストラクト
US12202856B2 (en) Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
AU2013246648B2 (en) Polypeptide useful in adoptive cell therapy
JP7519906B2 (ja) ホスホリパーゼa2受容体キメラ自己受容体t細胞の組成物および方法
AU2016250200B2 (en) Chimeric protein
CN113604491A (zh) 嵌合自身抗体受体t细胞的组合物和方法
US20250144137A1 (en) Nucleic acid constructs for expressing polypeptides in cells
JP2024019533A (ja) 膜結合型IL-10を発現する遺伝子的にリプログラミングされたTreg
US20250345429A1 (en) Compositions and methods comprising chimeric adaptor polypeptides
KR20220007675A (ko) 아세틸콜린 수용체 키메라 자가항체 수용체 세포의 조성물 및 방법
CN119053618A (zh) 嵌合ilt受体组合物和方法
US20240207405A1 (en) Il2 tethered to its receptor il2rbeta and pore-forming proteins as a platform to enhance immune cell activity
EP4731648A1 (en) Constitutive cytokine receptors
KR20230089464A (ko) 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
KR20230089462A (ko) 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
KR20220132401A (ko) 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250514

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250514

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250522

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250522

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250808

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250808

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250808

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250808

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250808